Efficacy of red-light photodynamic therapy with 10% ALA gel in relation to the epidermal extent of atypical keratinocytes in actinic keratosis - Retrospective exploratory analysis of three pivotal phase III trials

Main Article Content

E Bierhoff
MVZ Corius DermPathBonn GmbH, Heinz-Werner-Seifert-Institute of Dermatopathology

JL Cohen
AboutSkin Dermatology and AboutSkin Research

RM Szeimies
Department of Dermatology and Allergology, Klinikum Vest GmbH

U Reinhold
MVZ Dermatologisches Zentrum Bonn GmbH

T Dirschka
CentroDerm GmbH

Keywords

actinic keratosis, efficacy, red-light photodynamic therapy, 10% ALA gel, atypical keratinocytes, phase 3, clinical trial

References

1. Olsen EA, Abernethy ML, Kulp-Shorten C, et al., J Am Acad Dermatol 1991;24(5 Pt 1):738–43. PubMed PMID: 1869646

2. Schmitz L, Kahl P, Majores M, et al., J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1303-7. PMID: 26955898

3. Roewert-Huber J, Patel MJ, Forschner T, et al., Br J Dermatol 2007;156 Suppl 3:8–12. PubMed PMID: 17488400

4. Cockerell CJ. J Am. Acad. Dermatol 2000;42(1 Pt 2):11–7. PubMed PMID: 10607351

5. Clinical Study Report (ALA-AK-CT002), study design and results can be accessed via clinicaltrials.gov

6. Clinical Study Report (ALA-AK-CT003), study design and results can be accessed via clinicaltrials.gov

7. Clinical Study report (ALA-AK-CT007), study design and results can be accessed via clinicaltrials.gov

8. AMELUZ® (prescribing information). Woburn, MA: Biofrontera Inc.; 2021

9. Maisch T, Santarelli F, Schreml S, et al., Exp Dermatol. 2010; Aug;19(8):e302-5. doi: 10.1111/j.1600-0625.2009.01001.x. PMID: 19845760

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.93

Article Details

How to Cite
[1]
Bierhoff, E., Cohen, J., Szeimies, R., Reinhold, U. and Dirschka, T. 2022. Efficacy of red-light photodynamic therapy with 10% ALA gel in relation to the epidermal extent of atypical keratinocytes in actinic keratosis - Retrospective exploratory analysis of three pivotal phase III trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s93. DOI:https://doi.org/10.25251/skin.6.supp.93.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)